GeneDx Reports Strong Q2 2025 Earnings with Revenue Growth and Profitability
GeneDx (WGS) reported Q2 2025 earnings with total revenue of $102.7 million, a 49% increase year-over-year, and achieved a record adjusted gross margin of 71%. The company also raised its full-year revenue guidance to between $400 million and $415 million.
Tickers: $WGS
Topics: Acquisition Exome and Genome Testing Financial Guidance Profitability Revenue Growth